S&P 500   3,113.57 (-0.21%)
DOW   27,848.04 (-0.31%)
QQQ   202.92 (-0.22%)
CGC   17.75 (+15.86%)
BABA   183.19 (-1.11%)
T   36.59 (-3.71%)
ACB   2.67 (+14.13%)
F   8.78 (-1.35%)
PRI   132.65 (+0.77%)
DIS   147.50 (-0.59%)
S&P 500   3,113.57 (-0.21%)
DOW   27,848.04 (-0.31%)
QQQ   202.92 (-0.22%)
CGC   17.75 (+15.86%)
BABA   183.19 (-1.11%)
T   36.59 (-3.71%)
ACB   2.67 (+14.13%)
F   8.78 (-1.35%)
PRI   132.65 (+0.77%)
DIS   147.50 (-0.59%)
S&P 500   3,113.57 (-0.21%)
DOW   27,848.04 (-0.31%)
QQQ   202.92 (-0.22%)
CGC   17.75 (+15.86%)
BABA   183.19 (-1.11%)
T   36.59 (-3.71%)
ACB   2.67 (+14.13%)
F   8.78 (-1.35%)
PRI   132.65 (+0.77%)
DIS   147.50 (-0.59%)
S&P 500   3,113.57 (-0.21%)
DOW   27,848.04 (-0.31%)
QQQ   202.92 (-0.22%)
CGC   17.75 (+15.86%)
BABA   183.19 (-1.11%)
T   36.59 (-3.71%)
ACB   2.67 (+14.13%)
F   8.78 (-1.35%)
PRI   132.65 (+0.77%)
DIS   147.50 (-0.59%)
Log in

Marina Biotech Stock Price, Forecast & Analysis (OTCMKTS:MRNA)

Notice: This company has been marked as potentially delisted and may not be actively trading.
$19.94
+0.58 (+3.00 %)
(As of 11/20/2019 12:44 PM ET)
Today's Range
$19.35
Now: $19.94
$20.00
50-Day Range
$12.17
MA: $14.00
$15.31
52-Week Range
$11.54
Now: $19.94
$29.79
Volume570,823 shs
Average Volume1.15 million shs
Market Capitalization$6.56 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Marina Biotech, Inc., a biopharmaceutical company, engages in the development and commercialization of proprietary drug therapeutics primarily for hypertension, arthritis, pain, and oncology in the United States, Europe, and internationally. The company offers Prestalia, a single-pill fixed dose combination (FDC) of perindopril argenine, an angiotensin-converting-enzyme inhibitor; and amlodipine besylate, a calcium channel blocker for the treatment of hypertension. Its clinical development programs include IT-102 and IT-103, a celecoxib program drug candidates for the treatment of combined arthritis pain/hypertension and the treatment of pain requiring a high dose of celecoxib; CEQ508, an oral delivery of small interfering RNA against beta-catenin, combined with IT-102 to suppress polyps in the precancerous syndrome and orphan indication familial adenomatous polyposis; and CEQ508 combined with IT-103 to treat colorectal cancer. The company is headquartered in City of Industry, California.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:MRNA
Previous SymbolOTCMKTS:MRNAD
CUSIPN/A
Phone626-964-5788

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Market Cap$6.56 billion
Next Earnings DateN/A
OptionableNot Optionable

Receive MRNA News and Ratings via Email

Sign-up to receive the latest news and ratings for MRNA and its competitors with MarketBeat's FREE daily newsletter.


Marina Biotech (OTCMKTS:MRNA) Frequently Asked Questions

What is Marina Biotech's stock symbol?

Marina Biotech trades on the OTCMKTS under the ticker symbol "MRNA."

How were Marina Biotech's earnings last quarter?

Marina Biotech, Inc. (OTCMKTS:MRNA) issued its quarterly earnings results on Wednesday, November, 6th. The biotechnology company reported ($0.37) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.43) by $0.06. The biotechnology company had revenue of $17.05 million for the quarter, compared to analysts' expectations of $17.64 million. The firm's revenue for the quarter was down 59.2% on a year-over-year basis. During the same quarter last year, the company earned ($0.24) earnings per share. View Marina Biotech's Earnings History.

What price target have analysts set for MRNA?

5 brokerages have issued 1 year price targets for Marina Biotech's shares. Their forecasts range from $24.00 to $40.00. On average, they expect Marina Biotech's stock price to reach $31.00 in the next year. This suggests a possible upside of 55.5% from the stock's current price. View Analyst Price Targets for Marina Biotech.

What is the consensus analysts' recommendation for Marina Biotech?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Marina Biotech in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Marina Biotech.

Has Marina Biotech been receiving favorable news coverage?

Media stories about MRNA stock have been trending extremely negative this week, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Marina Biotech earned a news sentiment score of -5.0 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the next few days. View News Stories for Marina Biotech.

Who are some of Marina Biotech's key competitors?

What other stocks do shareholders of Marina Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Marina Biotech investors own include Intelsat (I), Bank of America (BAC), Fossil Group (FOSL), First Data (FDC), Associated British Foods (ABF), Chaarat Gold (CGH), AMC Entertainment (AMC), Apollo Global Management (APO), Ciena (CIEN) and Twilio (TWLO).

Who are Marina Biotech's key executives?

Marina Biotech's management team includes the folowing people:
  • Mr. Erik Emerson, Chief Commercial Officer & Director (Age 47)
  • Mr. Robert C. Moscato Jr., CEO & Director (Age 42)
  • Mr. Amit Shah, Chief Financial Officer (Age 52)
  • Mr. Mihir Munsif, Chief Operating Officer (Age 55)
  • Dr. Larn Hwang, Chief Scientific Officer (Age 55)

Who are Marina Biotech's major shareholders?

Marina Biotech's stock is owned by a number of of institutional and retail investors. Top institutional investors include Moloney Securities Asset Management LLC (0.04%), Boston Advisors LLC (0.01%) and Parallel Advisors LLC (0.00%). Company insiders that own Marina Biotech stock include Peter Barton Hutt and Stephane Bancel. View Institutional Ownership Trends for Marina Biotech.

Which institutional investors are selling Marina Biotech stock?

MRNA stock was sold by a variety of institutional investors in the last quarter, including Parallel Advisors LLC. Company insiders that have sold Marina Biotech company stock in the last year include Peter Barton Hutt and Stephane Bancel. View Insider Buying and Selling for Marina Biotech.

Which institutional investors are buying Marina Biotech stock?

MRNA stock was purchased by a variety of institutional investors in the last quarter, including Moloney Securities Asset Management LLC and Boston Advisors LLC. View Insider Buying and Selling for Marina Biotech.

What is Marina Biotech's stock price today?

One share of MRNA stock can currently be purchased for approximately $19.94.

How big of a company is Marina Biotech?

Marina Biotech has a market capitalization of $6.56 billion. View Additional Information About Marina Biotech.

What is Marina Biotech's official website?

The official website for Marina Biotech is http://www.marinabio.com/.

How can I contact Marina Biotech?

Marina Biotech's mailing address is 17870 CASTLETON STREET SUITE 250, CITY OF INDUSTRY CA, 91748. The biotechnology company can be reached via phone at 626-964-5788 or via email at [email protected]


MarketBeat Community Rating for Marina Biotech (OTCMKTS MRNA)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  134 (Vote Outperform)
Underperform Votes:  93 (Vote Underperform)
Total Votes:  227
MarketBeat's community ratings are surveys of what our community members think about Marina Biotech and other stocks. Vote "Outperform" if you believe MRNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MRNA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/20/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel